<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04528719</url>
  </required_header>
  <id_info>
    <org_study_id>mRNA-1345-P101</org_study_id>
    <nct_id>NCT04528719</nct_id>
  </id_info>
  <brief_title>A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive</brief_title>
  <official_title>A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Healthy Younger Adults Aged 18 to 49 Years, Women of Child-Bearing Potential Aged 18 to 40 Years, Healthy Older Adults Aged 65 to 79 Years, Japanese Older Adults Aged ≥ 60 Years, and RSV-Seropositive Children Aged 12 to 59 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ModernaTX, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ModernaTX, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to evaluate the tolerability and reactogenicity of a&#xD;
      single injection of 1 of up to 5 dose levels of mRNA-1345 in younger adults, women of&#xD;
      child-bearing potential, and older adults including Japanese older adults; of 3 injections of&#xD;
      the middle dose level of mRNA-1345 given 56 days apart in younger adults; of a booster&#xD;
      injection of mRNA-1345 given approximately 12 months after the primary injection in older&#xD;
      adults; and of 3 injections of 1 of 2 dose levels of mRNA-1345 given 56 days apart in&#xD;
      children who are RSV-seropositive.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)</measure>
    <time_frame>Up to Day 372 (7 days after each injection)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Unsolicited Adverse Events (AEs)</measure>
    <time_frame>Up to Day 393 (28 days after the last injection)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Serious AEs or Medically Attended AEs (MAAEs)</measure>
    <time_frame>Up to Day 730 (End of Study)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) of Serum RSV Neutralizing and Binding Antibodies (Abs)</measure>
    <time_frame>Up to Day 141 (Cohorts 5 and 6), up to Day 169 (Cohorts 1, 2, 4, 12, 13, and 14), up to Day 281 (Cohort 3), and up to Day 730 (Cohorts 7, 8, 9, 10, and 11)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold-Rise of Postbaseline/Baseline Ab Titers</measure>
    <time_frame>Up to Day 141 (Cohorts 5 and 6), up to Day 169 (Cohorts 1, 2, 4, 12, 13, and 14), up to Day 281 (Cohort 3), and up to Day 730 (Cohorts 7, 8, 9, 10, and 11)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with ≥2-fold and ≥4-fold Increases in Ab Titers from Baseline</measure>
    <time_frame>Up to Day 141 (Cohorts 5 and 6), up to Day 169 (Cohorts 1, 2, 4, 12, 13, and 14), up to Day 281 (Cohort 3), and up to Day 730 (Cohorts 7, 8, 9, 10, and 11)</time_frame>
  </secondary_outcome>
  <number_of_arms>15</number_of_arms>
  <enrollment type="Anticipated">645</enrollment>
  <condition>Respiratory Syncytial Virus</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Dose A in Younger Adults</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single injection of Dose A of mRNA-1345 or matching-placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Dose B in Younger Adults</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single injection of Dose B of mRNA-1345 or matching-placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Dose B in Younger Adults</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three total injections, 1 injection of either Dose B of mRNA-1345 or matching-placebo per day on Day 1, Day 57, and Day 113.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Dose C in Younger Adults</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single injection of Dose C of mRNA-1345 or matching-placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: Dose D in Children</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three total injections, 1 injection of either Dose D of mRNA-1345 or matching-placebo per day on Day 1, Day 57, and Day 113.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6: Dose B in Children</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three total injections, 1 injection of either Dose B of mRNA-1345 or matching-placebo per day on Day 1, Day 57, and Day 113.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7: Dose A in Older Adults</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two total injections, 1 injection of either Dose A of mRNA-1345 or matching-placebo per day on Day 1 and approximately 12 months later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8: Dose B in Older Adults</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two total injections, 1 injection of either Dose B of mRNA-1345 or matching-placebo per day on Day 1 and approximately 12 months later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 9: Dose C in Older Adults</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two total injections, 1 injection of either Dose C of mRNA-1345 or matching-placebo per day on Day 1 and approximately 12 months later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 10: Dose E in Older Adults</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two total injections, 1 injection of either Dose E of mRNA-1345 or matching-placebo per day on Day 1 and approximately 12 months later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 11: Dose F in Older Adults</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two total injections, 1 injection of either Dose F of mRNA-1345 or matching-placebo per day on Day 1 and approximately 12 months later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 12: Dose E in Women of Child-Bearing Potential</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single injection of Dose E of mRNA-1345 or matching-placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 13: Dose F in Women of Child-Bearing Potential</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single injection of Dose F of mRNA-1345 or matching-placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 14: Dose A in Women of Child-Bearing Potential</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single injection of Dose A of mRNA-1345 or matching-placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 15: Dose B in Japanese Older Adults</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single injection of Dose B of mRNA-1345 or matching-placebo on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mRNA-1345</intervention_name>
    <description>Formulation for injection</description>
    <arm_group_label>Cohort 10: Dose E in Older Adults</arm_group_label>
    <arm_group_label>Cohort 11: Dose F in Older Adults</arm_group_label>
    <arm_group_label>Cohort 12: Dose E in Women of Child-Bearing Potential</arm_group_label>
    <arm_group_label>Cohort 13: Dose F in Women of Child-Bearing Potential</arm_group_label>
    <arm_group_label>Cohort 14: Dose A in Women of Child-Bearing Potential</arm_group_label>
    <arm_group_label>Cohort 15: Dose B in Japanese Older Adults</arm_group_label>
    <arm_group_label>Cohort 1: Dose A in Younger Adults</arm_group_label>
    <arm_group_label>Cohort 2: Dose B in Younger Adults</arm_group_label>
    <arm_group_label>Cohort 3: Dose B in Younger Adults</arm_group_label>
    <arm_group_label>Cohort 4: Dose C in Younger Adults</arm_group_label>
    <arm_group_label>Cohort 5: Dose D in Children</arm_group_label>
    <arm_group_label>Cohort 6: Dose B in Children</arm_group_label>
    <arm_group_label>Cohort 7: Dose A in Older Adults</arm_group_label>
    <arm_group_label>Cohort 8: Dose B in Older Adults</arm_group_label>
    <arm_group_label>Cohort 9: Dose C in Older Adults</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% sodium chloride (normal saline) injection</description>
    <arm_group_label>Cohort 10: Dose E in Older Adults</arm_group_label>
    <arm_group_label>Cohort 11: Dose F in Older Adults</arm_group_label>
    <arm_group_label>Cohort 12: Dose E in Women of Child-Bearing Potential</arm_group_label>
    <arm_group_label>Cohort 13: Dose F in Women of Child-Bearing Potential</arm_group_label>
    <arm_group_label>Cohort 14: Dose A in Women of Child-Bearing Potential</arm_group_label>
    <arm_group_label>Cohort 15: Dose B in Japanese Older Adults</arm_group_label>
    <arm_group_label>Cohort 1: Dose A in Younger Adults</arm_group_label>
    <arm_group_label>Cohort 2: Dose B in Younger Adults</arm_group_label>
    <arm_group_label>Cohort 3: Dose B in Younger Adults</arm_group_label>
    <arm_group_label>Cohort 4: Dose C in Younger Adults</arm_group_label>
    <arm_group_label>Cohort 5: Dose D in Children</arm_group_label>
    <arm_group_label>Cohort 6: Dose B in Children</arm_group_label>
    <arm_group_label>Cohort 7: Dose A in Older Adults</arm_group_label>
    <arm_group_label>Cohort 8: Dose B in Older Adults</arm_group_label>
    <arm_group_label>Cohort 9: Dose C in Older Adults</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Healthy young adults ≥18 to ≤49 years of age, women of child-bearing potential ≥18 to&#xD;
             ≤40 years of age, healthy older adults ≥65 to &lt;80 years of age, Japanese older adults&#xD;
             ≥ 60 years of age, and children ≥12 to &lt; 60 months of age.&#xD;
&#xD;
          -  Willing and physically able to comply with protocol-mandated follow-up, including all&#xD;
             procedures.&#xD;
&#xD;
          -  Adult participant or parent(s)/legal guardian(s) of pediatric participants has&#xD;
             provided written informed consent for participation in this study, including all&#xD;
             evaluations and procedures as specified by the protocol.&#xD;
&#xD;
        Specific inclusion criteria for adults (younger adults, women of child-bearing potential,&#xD;
        and older adults [including Japanese older adults]):&#xD;
&#xD;
          -  Has a body mass index (BMI) from ≥18 kilogram (kg)/meter (m)^2 to ≤35 kg/m^2.&#xD;
&#xD;
          -  Female participants of non-child-bearing potential. This criterion does not apply for&#xD;
             women of child-bearing potential Cohorts 12, 13, and 14.&#xD;
&#xD;
          -  Female participants of child-bearing potential may be enrolled in the study, if the&#xD;
             participant: 1) has a negative urine pregnancy test at Screening and on the day of&#xD;
             vaccination; 2) has practiced adequate contraception or has abstained from all&#xD;
             activities that could lead to pregnancy for 28 days prior to vaccination; 3) has&#xD;
             agreed to continue adequate contraception through 3 months following the last&#xD;
             injection; and 4) is not currently breastfeeding.&#xD;
&#xD;
        Specific inclusion criteria for children 12 to 59 months of age:&#xD;
&#xD;
          -  Seropositive for RSV-neutralizing Abs at Screening.&#xD;
&#xD;
          -  Has received routine immunizations appropriate for age per local guidance.&#xD;
&#xD;
          -  Current height and weight above the third percentile for age.&#xD;
&#xD;
        Specific inclusion criteria for Japanese older adults:&#xD;
&#xD;
          -  Adult Japanese participants ≥ 60 years of age at the time of consent, who in the&#xD;
             opinion of the Investigator, are in good health based on review of medical history and&#xD;
             screening physical examination.&#xD;
&#xD;
          -  Japanese participants are defined as individuals born in Japan, with both parents and&#xD;
             4 grandparents who were born in Japan.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Has Screening laboratory values Grade ≥1 (younger adult, women of child-bearing&#xD;
             potential, and pediatric participants) or &gt;Grade 1 (older adult participants,&#xD;
             including Japanese older adult participants).&#xD;
&#xD;
          -  Is acutely ill or febrile on the day of the first injection.&#xD;
&#xD;
          -  Has a significant medical history, including but not limited to:&#xD;
&#xD;
               -  Congenital or acquired immunodeficiency, including human immunodeficiency virus&#xD;
                  (HIV) infection.&#xD;
&#xD;
               -  Chronic hepatitis or suspected active hepatitis.&#xD;
&#xD;
               -  Bleeding disorder that is considered a contraindication to intramuscular (IM)&#xD;
                  injection or phlebotomy.&#xD;
&#xD;
               -  Dermatologic conditions that could affect local solicited AR assessments.&#xD;
&#xD;
               -  Any history of allergic or anaphylactic reactions following a vaccination that&#xD;
                  required medical intervention.&#xD;
&#xD;
               -  Autoimmune disease except for Hashimoto's disease.&#xD;
&#xD;
          -  Receipt of:&#xD;
&#xD;
               -  Inactivated vaccine(s) within 14 days prior to first injection; or, plans to&#xD;
                  receive inactivated vaccine(s) within 14 days prior to and through 14 days&#xD;
                  following each study injection, with the exception of any COVID-19 vaccine&#xD;
                  (regardless of type of vaccine) that becomes available to the participant during&#xD;
                  the study; efforts should be made to space study vaccinations and COVID-19&#xD;
                  vaccinations by at least 7 and preferably 14 days, but COVID-19 vaccinations&#xD;
                  should not be delayed.&#xD;
&#xD;
               -  Live virus vaccine(s) within 28 days prior to first injection; or, plans to&#xD;
                  receive live virus vaccine(s) within 28 days prior to and through 28 days&#xD;
                  following each study injection.&#xD;
&#xD;
               -  Systemic immunosuppressants or immune-modifying drugs for &gt;14 days in total&#xD;
                  within 6 months prior to the day of enrollment. Topical tacrolimus is allowed if&#xD;
                  not used within 14 days prior to the day of enrollment. Inhaled, nasal, and&#xD;
                  topical steroids are allowed.&#xD;
&#xD;
               -  Intravenous blood products (red cells, platelets, and immunoglobulins [Ig])&#xD;
                  within 3 months prior to enrollment.&#xD;
&#xD;
          -  Has received a drug product containing lipid nanoparticles (LNPs) within 14 days&#xD;
             before enrollment, with the exception of any COVID-19 vaccine (regardless of type of&#xD;
             vaccine) that becomes available to the participant during the study; efforts should be&#xD;
             made to space study vaccinations and COVID-19 vaccinations by at least 7 and&#xD;
             preferably 14 days, but COVID-19 vaccinations should not be delayed.&#xD;
&#xD;
        Specific exclusion criteria for older adults:&#xD;
&#xD;
          -  Known history of poorly controlled hypertension (per determination of the&#xD;
             Investigator) or systolic blood pressure &gt;160 millimeters of mercury (mmHg) at the&#xD;
             Screening visit.&#xD;
&#xD;
          -  Known history of hypotension or systolic blood pressure &lt;85 mmHg at the Screening&#xD;
             visit.&#xD;
&#xD;
          -  Poorly controlled diabetes mellitus (per determination of the Investigator).&#xD;
&#xD;
          -  Diagnosis of significant chronic pulmonary disease (per determination of the&#xD;
             Investigator) (such as, chronic obstructive pulmonary disease, asthma).&#xD;
&#xD;
          -  Significant chronic cardiovascular disease (per determination of the Investigator).&#xD;
&#xD;
          -  Resides in a nursing home.&#xD;
&#xD;
          -  Anticipates the need for immunosuppressive treatment at any time during participation&#xD;
             in the study.&#xD;
&#xD;
          -  Diagnosis of malignancy within previous 10 years (excluding non-melanoma skin cancer&#xD;
             and cervical carcinoma in-situ).&#xD;
&#xD;
        Specific exclusion criteria for children 12 to 59 months of age:&#xD;
&#xD;
          -  Has received any monoclonal antibody at any time prior to Screening.&#xD;
&#xD;
          -  Prior hospitalization for RSV disease (confirmed by polymerase chain reaction).&#xD;
&#xD;
          -  Receipt of any prior systemic immunosuppressants or immune-modifying drugs.&#xD;
&#xD;
          -  Any history of febrile seizures (inclusive of single simple febrile seizure).&#xD;
&#xD;
          -  History of epilepsy.&#xD;
&#xD;
          -  History of meningitis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Moderna Clinical Trials</last_name>
    <phone>877-913-3286</phone>
    <email>clinicaltrials@modernatx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Baptist Health Center for Clinical Research</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Paradigm Clinical Research Institute Inc - ClinEdge - PPDS</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942-3189</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Palm Beach Research - ClinEdge - PPDS</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IResearch Atlanta LLC</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030-3438</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IACT Health - IACT - PPDS</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076-0927</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Atlanta - ERN-PPDS</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281-9054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synexus - Optimal Research - Peoria</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates - Newton</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114-9017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medpharmics</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brigham and Womens Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Novi</city>
        <state>Michigan</state>
        <zip>48377</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research-(Savannah Georgia) - Platinum - PPDS</name>
      <address>
        <city>Norfolk</city>
        <state>Nebraska</state>
        <zip>68701-2669</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research-(Omaha Nebraska) - Platinum - PPDS</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MedPharmics, LLC. - Albuquerque</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102-3876</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Global Medical Research - M3 WR - ERN - PPDS</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612-8104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research - Medford - ERN - PPDS</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504-9741</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Keystone VitaLink Research - Greenville - PPDS</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615-4833</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Keystone VitaLink Research - Spartanburg - PPDS</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303-4225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center For Pharmaceutical Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235-6262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc. - PPDS</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3539</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tanner Clinic</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 20, 2020</study_first_submitted>
  <study_first_submitted_qc>August 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2020</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Viral Diseases</keyword>
  <keyword>Messenger RNA</keyword>
  <keyword>Moderna</keyword>
  <keyword>mRNA-1345</keyword>
  <keyword>Respiratory syncytial virus</keyword>
  <keyword>RSV Seropositive</keyword>
  <keyword>Safety</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Vaccines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

